AUGAF
  • Home
  • Politics
  • Business
  • National
  • News
  • Finance
  • Technology
  • Sports
  • International
  • CommoditiesNew
  • Contact
No Result
View All Result
  • Home
  • Politics
  • Business
  • National
  • News
  • Finance
  • Technology
  • Sports
  • International
  • CommoditiesNew
  • Contact
No Result
View All Result
AUGAF
No Result
View All Result
Home Business

Abbot Pakistan Bottom Line Remain In Red For 9M 2023 on Cost Escalation

admin-augaf by admin-augaf
October 28, 2023
in Business, News
Reading Time: 2 mins read
0
Abbot Pakistan Bottom Line Remain In Red For 9M 2023 on Cost Escalation

An Abbott company logo is pictured at the reception of its office in Mumbai, India, September 8, 2015. AUGAF/REUTERS/Shailesh Andrade

Share on FacebookShare on TwitterWhatsapp

Karachi October 28 2023: Abbot Pakistan reported loss of PKR 792 million for the first nine months of current calender year due to significant devaluation of Pakistan Rupee.

Sales for the period increased by 12% over the same period last year. Pharmaceutical sales increased by 18% driven by sustained performance of established brands, while Nutritional sales decreased by 7% mainly on account of lower volumes following restrained demand due to inflationary pressures. Diagnostics segment registered a growth of 20% following price revisions taken during Q3-2023.

“The Company continues to face challenges of inflation and Rupee devaluation. The macroeconomic environment continues to pose significant external challenges which must be proactively addressed to ensure sustainable future of the pharmaceutical industry,” says Company Chief Executive Officer Syed Anis Ahmed.

“We hope that the Drug Regulatory Authority of Pakistan will play its due role in this unprecedented situation through conducting necessary pricing reviews and ensuring timely resolution of pending hardship cases. As a long-term measure, the Authority may consider introducing automatic mechanism and policy to offset the impact of devaluation. Notwithstanding, your Company remains dedicated to making all efforts to mitigate adverse impacts through productivity and cost containment initiatives,” he added.

Gross profit margin of the Company over this period was 20% vs 33% during the same period last year. It remained under pressure due to significant devaluation of Pakistani Rupee in Q1 2023 and increase in product costs.

Gross margin for the pharmaceutical segment declined to 21% from 32%, whereas the gross margin for Nutritional segment also declined to 22% from 40%.

Operating expenses increased by 14% on account of inflation. Other charges increased by 18% mainly on account of exchange losses due to devaluation of Pakistani Rupee during Q1-2023.

Tax charge for the period was PKR 1,762.4 million primarily on account of minimum tax regime and prior year super tax levy at the rate of 10% implemented through Finance Act 2023. Net loss for the period was PKR 792.7 million due to the reasons mentioned above.

Tags: AbbotPharmaceutical
admin-augaf

admin-augaf

Related Posts

Sazgar awarded Category-A Green filed Status
Business

Sazgar Haval Sales Dropped 42% in April 2025

May 12, 2025
New Trump Travel Ban Could Bar Afghans, Pakistanis Soon – Reuters
Business

US and China Agrees to Lower Tariffs for 90 Days

May 12, 2025
Virat Kohli Steps down As Indian Test Captain: ICC
Business

Era Over as Virat Kohli Retires from Test Cricket

May 12, 2025
Fair Global Consult Fair Global Consult Fair Global Consult
ADVERTISEMENT

Recent News

Sazgar awarded Category-A Green filed Status

Sazgar Haval Sales Dropped 42% in April 2025

May 12, 2025
New Trump Travel Ban Could Bar Afghans, Pakistanis Soon – Reuters

US and China Agrees to Lower Tariffs for 90 Days

May 12, 2025
Virat Kohli Steps down As Indian Test Captain: ICC

Era Over as Virat Kohli Retires from Test Cricket

May 12, 2025
Oil Prices Fall After Iran Attack As Market Draws Down Risk Premium

Oil Prices Jump Over 3% on US-China Tariff Reductions

May 12, 2025
SHIFA Hospital profitability to Increase after addition of new Facilities: Insight Securities

Shifa International Hospitals to Acquire Full Ownership of Shifa Islamabad Medical Centre

May 12, 2025

Popular News

  • NSS

    President Prohibit National Savings For Changing Rates on Existing Certificates Retrospectively

    0 shares
    Share 0 Tweet 0
  • Pakistan Rupee Appreciate against Dollar in Interbank as IMF Confirmed Board Review Date

    0 shares
    Share 0 Tweet 0
  • Pakistan Rupee Fall After 13 Days of Successive Gains against Dollar on Lower Remittances and Strengthening of US Dollar

    0 shares
    Share 0 Tweet 0
  • Petrol Prices in Pakistan to Return to July 2023 Levels

    0 shares
    Share 0 Tweet 0
  • Pakistan Central Bank Issued Show Cause Notice to Eight Banks Over Currency Speculation

    0 shares
    Share 0 Tweet 0

Categories

  • Budget
  • Business
  • Culture
  • Finance
  • International
  • National
  • News
  • Politics
  • PTI
  • Sports
  • Technology
AUGAF Logo

Follow us on social media:

Recent News

  • Sazgar Haval Sales Dropped 42% in April 2025
  • US and China Agrees to Lower Tariffs for 90 Days
  • Era Over as Virat Kohli Retires from Test Cricket

Category

  • Budget
  • Business
  • Culture
  • Finance
  • International
  • National
  • News
  • Politics
  • PTI
  • Sports
  • Technology

Recent News

Sazgar awarded Category-A Green filed Status

Sazgar Haval Sales Dropped 42% in April 2025

May 12, 2025
New Trump Travel Ban Could Bar Afghans, Pakistanis Soon – Reuters

US and China Agrees to Lower Tariffs for 90 Days

May 12, 2025
  • Home
  • Politics
  • News
  • Business
  • National
  • Finance
  • Technology
  • International

© 2021 AUGAF.

No Result
View All Result
  • Home
  • Politics
  • Business
  • National
  • News
  • Finance
  • Technology
  • Sports
  • International
  • Commodities
  • Contact

© 2021 AUGAF.